Specifications include, but are not limited to: a) The OSPHL has been performing hemoglobinopathy (sickle cell disease and traits) screening since 1995 utilizing the PerkinElmer RESOLVE Neonatal Hemoglobin Test kit and JB-2 Staining System designed for use with isoelectric focusing (IEF). OSPHL already possesses the testing equipment platform that utilizes the RESOLVE Neonatal Test Kit and JB-2 Staining System. No other FDAapproved test kit presently available can be used with the testing system used by and in possession of the OSPHL for this particular screening. b) OHA intends to enter into a contract for a 5-year term. OHA reserves the right to extend this term for additional periods of time not exceeding a total contract term of 10 years. Extensions of this contract term, and any subsequent change in pricing will be subject to written amendment and agreement by the parties to the contract. c) PerkinElmer is the only known supplier of an FDA approved product for the detection of neonatal hemoglobinopathies utilizing dried blood spots and the IEF method. This is the system currently in use by the OSPHL. Please note: This is a Sole Source Notification.
